Prognostic Significance of Human Epidermal Growth Factor Receptor Positivity for the Development of Brain Metastasis After Newly Diagnosed Breast Cancer

Our study shows that newly diagnosed human epidermal growth factor receptor 2 –overexpressing breast cancer patients are at increased risk for brain metastases

Zsolt Gabos

2006

Scholarcy highlights

  • To determine the incidence of brain metastases in human epidermal growth factor receptor 2–overexpressing patients, we analyzed a cohort of newly diagnosed 301 HER-2–positive and 363 HER-2–negative patients identified between January 1998 and December 2003
  • Our study shows that newly diagnosed HER-2–overexpressing breast cancer patients are at increased risk for brain metastases
  • In our population-based study, we investigated the relationship between HER-2 overexpression and the risk of brain metastasis in newly diagnosed breast cancer patients treated in our center between January 1998 and December 2003, comparing patients with and without HER-2 overexpression
  • We have shown that HER-2–overexpressing breast cancer patients are at an independently higher risk to develop brain metastasis compared with HER-2–negative patients, and we have confirmed that HER-2–overexpressing metastatic breast cancer patients represent a high-risk group for brain metastasis
  • We found that 9.0% of HER-2–overexpressing breast cancer patients developed brain metastases compared with 1.9% of HER-2–negative patients
  • The incidence of brain metastases in MBC patients receiving trastuzumab-based therapies varied from 28% to 42%.20-23
  • Our study shows that newly diagnosed human epidermal growth factor receptor 2–overexpressing breast cancer patients are at significantly increased risk for brain metastasis

Need more features? Save interactive summary cards to your Scholarcy Library.